Hepatitis C: the End of the Beginning and Possibly the Beginning of the End

Overview

Journal Ann Intern Med

Specialty General Medicine

Date 2012 Feb 22

PMID 22351718

Citations 19

Authors

Harvey J Alter

T Jake Liang

Affiliations

Soon will be listed here.

Citing Articles

Spatiotemporal Phylodynamics of Hepatitis C Among People Who Inject Drugs in India.

Clipman S, Mehta S, Rodgers M, Duggal P, Srikrishnan A, Saravanan S Hepatology. 2021; 74(4):1782-1794.

PMID: 34008172 PMC: 8756458. DOI: 10.1002/hep.31912.

Patterns in Liver-Related Health Outcomes with Hepatitis C Virus Treatments and Health Equity Implications for Decision Makers: A Cohort Analysis of Medicaid Patients.

Mantravadi S Health Equity. 2018; 1(1):156-164.

PMID: 30283843 PMC: 6071889. DOI: 10.1089/heq.2017.0018.

Genotyping & diagnostic methods for hepatitis C virus: A need of low-resource countries.

Kumar A, Rajput M, Paliwal D, Yadav A, Chhabra R, Singh S Indian J Med Res. 2018; 147(5):445-455.

PMID: 30082568 PMC: 6094507. DOI: 10.4103/ijmr.IJMR_1850_16.

Respondent-driven sampling for identification of HIV- and HCV-infected people who inject drugs and men who have sex with men in India: A cross-sectional, community-based analysis.

Solomon S, McFall A, Lucas G, Srikrishnan A, Kumar M, Anand S PLoS Med. 2017; 14(11):e1002460.

PMID: 29182638 PMC: 5705124. DOI: 10.1371/journal.pmed.1002460.

Arabinoxylan rice bran (Biobran) suppresses the viremia level in patients with chronic HCV infection: A randomized trial.

Salama H, Medhat E, Shaheen M, Zekri A, Darwish T, Ghoneum M Int J Immunopathol Pharmacol. 2016; 29(4):647-653.

PMID: 27799299 PMC: 5806823. DOI: 10.1177/0394632016674954.

References

Liu S, Cipriano L, Holodniy M, Owens D, Goldhaber-Fiebert J . New protease inhibitors for the treatment of chronic hepatitis C: a cost-effectiveness analysis. Ann Intern Med. 2012; 156(4):279-90. PMC: 3586733. DOI: 10.7326/0003-4819-156-4-201202210-00005. View

Culver D, Alter M, Mullan R, Margolis H . Evaluation of the effectiveness of targeted lookback for HCV infection in the United States-interim results. Transfusion. 2000; 40(10):1176-81. DOI: 10.1046/j.1537-2995.2000.40101176.x. View

Ly K, Xing J, Klevens R, Jiles R, Ward J, Holmberg S . The increasing burden of mortality from viral hepatitis in the United States between 1999 and 2007. Ann Intern Med. 2012; 156(4):271-8. DOI: 10.7326/0003-4819-156-4-201202210-00004. View

Zeuzem S, Buggisch P, Agarwal K, Marcellin P, Sereni D, Klinker H . The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C. Hepatology. 2011; 55(3):749-58. DOI: 10.1002/hep.24744. View

Alter H, Purcell R, Shih J, Melpolder J, Houghton M, Choo Q . Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med. 1989; 321(22):1494-500. DOI: 10.1056/NEJM198911303212202. View

Davis G, Alter M, El-Serag H, Poynard T, Jennings L . Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology. 2009; 138(2):513-21, 521.e1-6. DOI: 10.1053/j.gastro.2009.09.067. View

Zeuzem S, Andreone P, Pol S, Lawitz E, Diago M, Roberts S . Telaprevir for retreatment of HCV infection. N Engl J Med. 2011; 364(25):2417-28. DOI: 10.1056/NEJMoa1013086. View

Mitchell A, Colvin H, Beasley R . Institute of Medicine recommendations for the prevention and control of hepatitis B and C. Hepatology. 2010; 51(3):729-33. DOI: 10.1002/hep.23561. View

Chayama K, Takahashi S, Toyota J, Karino Y, Ikeda K, Ishikawa H . Dual therapy with the nonstructural protein 5A inhibitor, daclatasvir, and the nonstructural protein 3 protease inhibitor, asunaprevir, in hepatitis C virus genotype 1b-infected null responders. Hepatology. 2011; 55(3):742-8. DOI: 10.1002/hep.24724. View

10.

Pawlotsky J, Chevaliez S, McHutchison J . The hepatitis C virus life cycle as a target for new antiviral therapies. Gastroenterology. 2007; 132(5):1979-98. DOI: 10.1053/j.gastro.2007.03.116. View

11.

Rein D, Smith B, Wittenborn J, Lesesne S, Wagner L, Roblin D . The cost-effectiveness of birth-cohort screening for hepatitis C antibody in U.S. primary care settings. Ann Intern Med. 2011; 156(4):263-70. PMC: 5484577. DOI: 10.7326/0003-4819-156-4-201202210-00378. View

12.

Hoofnagle J, Seeff L . Peginterferon and ribavirin for chronic hepatitis C. N Engl J Med. 2006; 355(23):2444-51. DOI: 10.1056/NEJMct061675. View

13.

Choo Q, Kuo G, Weiner A, Overby L, Bradley D, Houghton M . Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science. 1989; 244(4902):359-62. DOI: 10.1126/science.2523562. View

14.

Ghany M, Nelson D, Strader D, Thomas D, Seeff L . An update on treatment of genotype 1 chronic hepatitis C virus infection: 2011 practice guideline by the American Association for the Study of Liver Diseases. Hepatology. 2011; 54(4):1433-44. PMC: 3229841. DOI: 10.1002/hep.24641. View

15.

Poordad F, McCone Jr J, Bacon B, Bruno S, Manns M, Sulkowski M . Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 2011; 364(13):1195-206. PMC: 3766849. DOI: 10.1056/NEJMoa1010494. View